Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease

Chad Mire, Joan B. Geisbert, Krystle N. Agans, Krista M. Versteeg, Daniel J. Deer, Benjamin A. Satterfield, Karla A. Fenton, Thomas Geisbert

Research output: Contribution to journalArticle

Abstract

Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal disease than NiVM. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiVB challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiVB model of human infection.

Original languageEnglish (US)
Pages (from-to)1144-1152
Number of pages9
JournalEmerging infectious diseases
Volume25
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Nipah Virus
Vesicular Stomatitis
Virus Diseases
Primates
Vaccines
Viruses
Injections
Cercopithecus aethiops
Bangladesh
Malaysia
Mortality
Singapore
Zoonoses
Neutralizing Antibodies
Disease Outbreaks
India
Glycoproteins
Immunoglobulin G

Keywords

  • Henipavirus
  • Nipah virus
  • nonhuman primates
  • vaccines
  • vesicular stomatitis virus
  • viruses
  • zoonoses

ASJC Scopus subject areas

  • Epidemiology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. / Mire, Chad; Geisbert, Joan B.; Agans, Krystle N.; Versteeg, Krista M.; Deer, Daniel J.; Satterfield, Benjamin A.; Fenton, Karla A.; Geisbert, Thomas.

In: Emerging infectious diseases, Vol. 25, No. 6, 01.06.2019, p. 1144-1152.

Research output: Contribution to journalArticle

Mire, Chad ; Geisbert, Joan B. ; Agans, Krystle N. ; Versteeg, Krista M. ; Deer, Daniel J. ; Satterfield, Benjamin A. ; Fenton, Karla A. ; Geisbert, Thomas. / Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease. In: Emerging infectious diseases. 2019 ; Vol. 25, No. 6. pp. 1144-1152.
@article{066fea1373414809a1dc9b31b1621a5c,
title = "Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease",
abstract = "Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998-1999 in Malaysia and Singapore (≈40{\%} CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80{\%} CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal disease than NiVM. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiVB challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiVB model of human infection.",
keywords = "Henipavirus, Nipah virus, nonhuman primates, vaccines, vesicular stomatitis virus, viruses, zoonoses",
author = "Chad Mire and Geisbert, {Joan B.} and Agans, {Krystle N.} and Versteeg, {Krista M.} and Deer, {Daniel J.} and Satterfield, {Benjamin A.} and Fenton, {Karla A.} and Thomas Geisbert",
year = "2019",
month = "6",
day = "1",
doi = "10.3201/eid2506.181620",
language = "English (US)",
volume = "25",
pages = "1144--1152",
journal = "Emerging Infectious Diseases",
issn = "1080-6040",
publisher = "Centers for Disease Control and Prevention (CDC)",
number = "6",

}

TY - JOUR

T1 - Use of Single-Injection Recombinant Vesicular Stomatitis Virus Vaccine to Protect Nonhuman Primates Against Lethal Nipah Virus Disease

AU - Mire, Chad

AU - Geisbert, Joan B.

AU - Agans, Krystle N.

AU - Versteeg, Krista M.

AU - Deer, Daniel J.

AU - Satterfield, Benjamin A.

AU - Fenton, Karla A.

AU - Geisbert, Thomas

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal disease than NiVM. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiVB challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiVB model of human infection.

AB - Nipah virus (NiV) is a zoonotic pathogen that causes high case-fatality rates (CFRs) in humans. Two NiV strains have caused outbreaks: the Malaysia strain (NiVM), discovered in 1998-1999 in Malaysia and Singapore (≈40% CFR); and the Bangladesh strain (NiVB), discovered in Bangladesh and India in 2001 (≈80% CFR). Recently, NiVB in African green monkeys resulted in a more severe and lethal disease than NiVM. No NiV vaccines or treatments are licensed for human use. We assessed replication-restricted single-injection recombinant vesicular stomatitis vaccine NiV vaccine vectors expressing the NiV glycoproteins against NiVB challenge in African green monkeys. All vaccinated animals survived to the study endpoint without signs of NiV disease; all showed development of NiV F Ig, NiV G IgG, or both, as well as neutralizing antibody titers. These data show protective efficacy against a stringent and relevant NiVB model of human infection.

KW - Henipavirus

KW - Nipah virus

KW - nonhuman primates

KW - vaccines

KW - vesicular stomatitis virus

KW - viruses

KW - zoonoses

UR - http://www.scopus.com/inward/record.url?scp=85066962544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066962544&partnerID=8YFLogxK

U2 - 10.3201/eid2506.181620

DO - 10.3201/eid2506.181620

M3 - Article

VL - 25

SP - 1144

EP - 1152

JO - Emerging Infectious Diseases

JF - Emerging Infectious Diseases

SN - 1080-6040

IS - 6

ER -